← Back

Lexaria Bioscience Corp

Lexaria Bioscience Corp. is a biotechnology company that offers its patented drug delivery platform technology, DehydraTECH. This technology combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds to improve bloodstream entry, increase effectiveness, allow lower dosing for better tolerability, and promote healthier oral ingestion. DehydraTECH is used with a range of active molecules, including GLP-1 and GIP drugs, vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, nicotine and its analogs, and cannabinoids. It is applied to therapeutic indications such as diabetes, weight loss, hypertension, epilepsy, and heart disease, and is implemented in various ingestible or topically administered formats, including oral suspensions, tablets, capsules, foods, beverages, and oral products, suitable for pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Incorporated in 2004, it is headquartered in Kelowna, Canada.

Country
Price · split & dividend adjusted
News & notes moving LEXX
LEXX

Lexaria Bioscience Sets August 3 Effective Date for 1-for-15 Reverse Stock Split

Lexaria Bioscience Corp. announced it will effect a 1-for-15 reverse stock split effective August 3, 2026, to regain compliance with Nasdaq's minimum $1.00 bid price requirement. The reverse split will consolidate the company's current 24,787,446 issued common shares into approximately 1,652,518 shares, with fractional shares rounded up, and will also proportionally adjust authorized shares from 220 million to about 14.67 million as well as outstanding convertible securities and their exercise prices. CEO Richard Christopher stated the move is critical for maintaining the Nasdaq listing and supporting business development and investor appeal amid recent equity market weakness. The company noted it examined 24 other reverse splits by Nasdaq-listed biotech firms in the first half of 2026, which averaged a 1-for-18 ratio. Following the split, shares will continue trading under the symbol LEXX with a new CUSIP number, and the company expects to comply with the minimum price rule by mid-August.
LEXX
ACCESS Newswire·50dRead more →
Biotech & Genomic Medicine▲

Lexaria Begins Dosing in Human Study of Oral DehydraTECH-Semaglutide

Lexaria Bioscience announced that dosing began on schedule on June 14th for Human Pilot Study #7, a five-week trial evaluating two oral DehydraTECH-semaglutide compositions against Novo Nordisk's Wegovy tablets. The study is investigating safety, tolerability, and pharmacokinetic properties across three arms, comparing SNAC-inclusive DHT-sema formulations in both tablet and capsule formats to the commercially available Wegovy tablets. For the first time, Lexaria is using an oral tablet DHT-sema composition designed to mimic certain physical properties of Novo's Rybelsus and Wegovy tablets, and both test articles incorporate SNAC in a multi-dose, multi-week human study. The five-week duration is intended to allow achievement of steady-state drug concentrations, and results are expected to be reviewed by the pharmaceutical industry for potential commercial relationships. The study is fully funded from existing corporate resources.
LEXX ▲NOV.XETRA
Biotech & Genomic Medicine
Lexaria Bioscience Corp.·85dRead more →
© 2026 MarketDXAsset